Evidence map›Paper›PMID 26451296›Full record

ArticleOncoimmunology2015

High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.

Mathieu F Chevalier, Sara Bobisse, Carla Costa-Nunes, Valérie Cesson, Patrice Jichlinski, Daniel E Speiser, Alexandre Harari, George Coukos, Pedro Romero, Denise Nardelli-Haefliger and 2 more

Abstract read
In one paragraph

Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. In Vitro Evaluation of Bunyavirus T Cell Immunity.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mathieu F ChevalierUrology Research Unit; Department of Urology; University Hospital of Lausanne (CHUV) ; Lausanne, Switzerland.
Sara BobisseCenter of Experimental Therapeutics; Department of Oncology; University Hospital of Lausanne ; Lausanne, Switzerland ; Ludwig Center for Cancer Research at University of Lausanne ; Epalinges, Switzerland.
Carla Costa-NunesLudwig Center for Cancer Research at University of Lausanne ; Epalinges, Switzerland.
Valérie CessonUrology Research Unit; Department of Urology; University Hospital of Lausanne (CHUV) ; Lausanne, Switzerland.
Patrice JichlinskiUrology Research Unit; Department of Urology; University Hospital of Lausanne (CHUV) ; Lausanne, Switzerland.
Daniel E SpeiserLudwig Center for Cancer Research at University of Lausanne ; Epalinges, Switzerland.
Alexandre HarariCenter of Experimental Therapeutics; Department of Oncology; University Hospital of Lausanne ; Lausanne, Switzerland ; Ludwig Center for Cancer Research at University of Lausanne ; Epalinges, Switzerland.
George CoukosLudwig Center for Cancer Research at University of Lausanne ; Epalinges, Switzerland ; Ovarian Cancer Research Center; Perelman School of Medicine; University of Pennsylvania ; Philadelphia, PA USA ; Department of Oncology; University Hospital of Lausanne (CHUV) ; Lausanne, Switzerland.
Pedro RomeroLudwig Center for Cancer Research at University of Lausanne ; Epalinges, Switzerland.
Denise Nardelli-HaefligerUrology Research Unit; Department of Urology; University Hospital of Lausanne (CHUV) ; Lausanne, Switzerland.
Camilla JandusLudwig Center for Cancer Research at University of Lausanne ; Epalinges, Switzerland.
Laurent DerréUrology Research Unit; Department of Urology; University Hospital of Lausanne (CHUV) ; Lausanne, Switzerland.

Funding

Swiss National Science Foundation 146638
6 · The paper itself

Abstract

In immune intervention trials, the comprehensive investigation of immunogenicity or T-cell epitope-mapping is challenging especially when a large set of epitopes needs to be screened and limited sample material is available. To this end, T-cell responses are often monitored using peptide pools. Here, we assessed the magnitude and sensitivity of detection of antigen-specific CD8

Indexed as

immune monitoringpeptide poolstumor-associated antigenstumor-specific T cellsvaccine trials

Identifiers

PMID26451296
PMCPMC4590008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.